Evidence map›Paper›PMID 42905237›Full record

ReviewCurrent osteoporosis reports2026

Osteoporosis and Alzheimer's Disease: The Role of Sclerostin.

Lorelé Gagiano, Ziming Chen, William G Blakeney, Christopher Jones, Frank Mastaglia, Minghao Zheng, Jun Yuan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lorelé GagianoSchool of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia.
Ziming ChenCentre for Translational Orthopaedic Research, School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia.
William G BlakeneyDepartment of Orthopaedic Surgery, Royal Perth Hospital, Wellington Street, Perth, WA, 6000, Australia.
Christopher JonesDepartment of Orthopaedic Surgery, Fremantle and Fiona Stanley Hospitals, Perth, WA, 6150, Australia.ORCID http://orcid.org/0000-0001-7283-626X
Frank MastagliaPerron Institute for Neurological and Translational Science, The University of Western Australia, 8 Verdun St, Nedlands, WA, 6009, Australia.
Minghao ZhengCentre for Translational Orthopaedic Research, School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia. minghao.zheng@uwa.edu.au.
Jun YuanCentre for Translational Orthopaedic Research, School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Perth, WA, 6009, Australia. jun.yuan@perron.uwa.edu.au.ORCID http://orcid.org/0000-0001-6542-4654

Funding

Perpetual IPAP2023/1338
6 · The paper itself

Abstract

purpose of reviewLittle is known about the underlying cause contributing to the association between Osteoporosis (OP) and Alzheimer's disease (AD). This review highlights the emerging role of sclerostin, a protein mainly produced by osteocytes, in the newly discovered crosstalk between bone and brain, with a focus on its potential contribution to the relationship between OP and AD. RECENT

findingsCirculating sclerostin levels increase with aging and are positively associated with brain amyloid-β burden in older adults. Studies demonstrate that elevated sclerostin can cross the blood-brain barrier, promote amyloid-β peptide deposition, and impair synaptic plasticity by suppressing Wnt/β-catenin signalling, whereas sclerostin inhibition restores neuronal plasticity and attenuates AD pathology. Sclerostin represents a promising target in the bone-brain interaction pathway. Its dual role as a measurable circulating biomarker and a modifiable component offers new opportunities for early risk assessment and therapeutic repurposing. Future longitudinal and interventional studies are essential to confirm the association between sclerostin and risk of AD, and to clarify whether targeting sclerostin can delay the onset of the disease or modify its trajectory.

Indexed as

Adaptor Proteins, Signal TransducingAlzheimer DiseaseBrainOsteoporosisAgingAmyloid beta-PeptidesBiomarkersBlood-Brain BarrierGenetic MarkersHumansNeuronal PlasticityWnt Signaling PathwayAdaptor Proteins, Signal TransducingAmyloid beta-PeptidesBiomarkersGenetic MarkersSOST protein, humanAgingAlzheimer’s diseaseBone-brain axisOsteoporosisSclerostinWnt/β-catenin

Identifiers

PMID42905237
PMCPMC13687117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.